Report of Foreign Issuer (6-k)
September 26 2018 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 25, 2018
001-36686
(Commission file number)
Forward Pharma A/S
(Translation of registrant’s name
into English)
Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
(Address of principal executive office)
________________________________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [ ] No [ X ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [ ] No [ X ]
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934. Yes [ ] No [ X ]
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): N/A
Item 1.
|
|
Company Presentation
|
On September 25, 2018, Forward Pharma A/S
(the “Company”) made available an updated investor presentation on its website. A copy of the investor presentation
is attached hereto as Exhibit 99.1.
The fact that this presentation is being made
available and filed herewith should not be deemed an admission as to the materiality of any information contained in the materials.
The information contained in the presentation is being provided as of September 25, 2018 and the Company does not undertake any
obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Date: September 25, 2018
|
|
|
|
Forward Pharma A/S
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Claus Bo Svendsen
|
|
|
|
|
|
|
Name: Claus Bo Svendsen
|
|
|
|
|
|
|
Title: Chief Executive Officer
|
EXHIBIT INDEX
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Apr 2023 to Apr 2024